In Brief: Texas Biotechnology Novastan
Executive Summary
Texas Biotechnology Novastan: SmithKline Beecham will co-develop and market argatroban in North America as anticoagulant therapy in patients with heparin-induced thrombocytopenia. The deal is worth up to $31.5 mil. to Texas Biotech, which expects to complete filing the Novastan NDA in August...